These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 21452513)

  • 41. Meningococcal vaccine against serogroups A, C, Y and W-135: new preparation. Encouraging immunogenicity studies.
    Prescrire Int; 2002 Apr; 11(58):35-8. PubMed ID: 11987309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2009 Apr; 35(ACS-3):1-40. PubMed ID: 19400026
    [No Abstract]   [Full Text] [Related]  

  • 43. [Quadrivalent meningococcal conjugate vaccine].
    Landry P
    Rev Med Suisse; 2011 May; 7(294):1006-8, 1010. PubMed ID: 21692314
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998.
    Brundage JF; Ryan MA; Feighner BH; Erdtmann FJ
    Clin Infect Dis; 2002 Dec; 35(11):1376-81. PubMed ID: 12439801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In brief: prevention of meningococcus B disease.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):97. PubMed ID: 24322662
    [No Abstract]   [Full Text] [Related]  

  • 46. Considerations for controlling invasive meningococcal disease in high income countries.
    Holst J; Nøkleby H; Bettinger JA
    Vaccine; 2012 May; 30 Suppl 2():B57-62. PubMed ID: 22607900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
    Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B
    Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine.
    Boccadifuoco G; Brunelli B; Pizza MG; Giuliani MM
    J Prev Med Hyg; 2012 Jun; 53(2):56-60. PubMed ID: 23240161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meningococcal vaccines.
    Collins CL; Pollard AJ
    Curr Opin Investig Drugs; 2002 Jul; 3(7):975-9. PubMed ID: 12186274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Anti-meningococcal vaccines].
    Taha MK; Alonso JM
    Rev Prat; 2008 Dec; 58(19):2099-101. PubMed ID: 19213536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The changing and dynamic epidemiology of meningococcal disease.
    Halperin SA; Bettinger JA; Greenwood B; Harrison LH; Jelfs J; Ladhani SN; McIntyre P; Ramsay ME; Sáfadi MA
    Vaccine; 2012 May; 30 Suppl 2():B26-36. PubMed ID: 22178525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Meningococcal vaccines: present status and perspectives].
    Alonso JM; Taha MK
    Therapie; 2005; 60(3):283-6. PubMed ID: 16128272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meningococcal serogroup B infections: a search for a broadly protective vaccine.
    Vermont CL; van den Dobbelsteen GP
    Expert Rev Vaccines; 2003 Oct; 2(5):673-81. PubMed ID: 14711328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 56. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.
    Giuliani MM; Biolchi A; Serruto D; Ferlicca F; Vienken K; Oster P; Rappuoli R; Pizza M; Donnelly J
    Vaccine; 2010 Jul; 28(31):5023-30. PubMed ID: 20493284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines.
    Pace D; Cuschieri P; Galea Debono A; Attard-Montalto S
    Vaccine; 2008 Nov; 26(47):5952-6. PubMed ID: 18801401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serogroup B meningococcal vaccines-an unfinished story.
    Sadarangani M; Pollard AJ
    Lancet Infect Dis; 2010 Feb; 10(2):112-24. PubMed ID: 20113980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serologic correlates of protection for evaluating the response to meningococcal vaccines.
    Balmer P; Borrow R
    Expert Rev Vaccines; 2004 Feb; 3(1):77-87. PubMed ID: 14761245
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccines for prevention of group B meningococcal disease: Not your father's vaccines.
    Harrison LH
    Vaccine; 2015 Nov; 33 Suppl 4():D32-8. PubMed ID: 26116255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.